ReviewThe Journal of allergy and clinical immunology2020
Eosinophil responses during COVID-19 infections and coronavirus vaccination.
Review in The Journal of allergy and clinical immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 193 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
193 citing papers in PubMed, 5 syntheses or guidelines pooled it, 372 citations in OpenAlex.
- Identification of Parameters Representative of Immune Dysfunction in Patients with Severe and Fatal COVID-19 Infection: a Systematic Review and Meta-analysis.Clinical reviews in allergy & immunology · 2023Pooled it
- A composite ranking of risk factors for COVID-19 time-to-event data from a Turkish cohort.Computational biology and chemistry · 2022Pooled it
- Silent existence of eosinopenia in sepsis: a systematic review and meta-analysis.BMC infectious diseases · 2021Pooled it
- A meta-analysis of SARS-CoV-2 patients identifies the combinatorial significance of D-dimer, C-reactive protein, lymphocyte, and neutrophil values as a predictor of disease severity.International journal of laboratory hematology · 2021Pooled it
- Prevalence of Comorbid Asthma and Related Outcomes in COVID-19: A Systematic Review and Meta-Analysis.The journal of allergy and clinical immunology. In practice · 2021Pooled it
- Comparable safety and non-inferior immunogenicity of the SARS-CoV-2 mRNA vaccine candidate PTX-COVID19-B and BNT162b2 in a phase 2 randomized, observer-blinded study.Scientific reports · 2024Trial
- Compartmental immunophenotyping in COVID-19 ARDS: A case series.The Journal of allergy and clinical immunology · 2021Trial
- COVID-19, the disease that changed the world.Medicine and pharmacy reports · 2026Review
- Characterisation of a cohort of opportunistically recruited patients with COVID-19 and approaches to patient stratification.BMC infectious diseases · 2026Article
- New Simplified White Blood Cells Score Improves Mortality Prediction in Severe COVID-19 Patients.Journal of clinical medicine · 2026Article
- Investigation of Biomarkers in Allergic Patients with Long COVID.Journal of personalized medicine · 2026Article
- Immunological Mechanisms Underlying Allergy Predisposition After SARS-CoV-2 Infection in Children.Cells · 2025Review
- Assessment of smoking exposure by urine cotinine levels in severe COVID-19 patients: a case-control study.Scientific reports · 2025Observational
- Article
- COVID-19-associated changes in nasal mucosa: Insights from inflammatory and epithelial cell profiling.Journal of family medicine and primary care · 2025Article
- Unexpected hypereosinophilia after Sinopharm vaccination: a case report.BMC infectious diseases · 2025Article
- Unveiling the prevalence and impact of silent rhinovirus infection in chronic rhinosinusitis with nasal polyps.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2025Article
- Machine learning-based model for predicting all-cause mortality in severe pneumonia.BMJ open respiratory research · 2025Article
- Eosinopenia predicts poor outcomes in patients with lung cancer with the omicron variant of COVID-19.Frontiers in medicine · 2025Article
- The Association of Blood Eosinophils and Neutrophils Expressing Eosinophilic Surface Markers with the Severity and Outcome of COVID-19.Microorganisms · 2024Article
133 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eosinophils are circulating and tissue-resident leukocytes that have potent proinflammatory effects in a number of diseases. Recently, eosinophils have been shown to have various other functions, including immunoregulation and antiviral activity. Eosinophil levels vary dramatically in a number of clinical settings, especially following eosinophil-targeted therapy, which is now available to selectively deplete these cells. There are key coronavirus disease 2019 (COVID-19)-related questions concerning eosinophils whose answers affect recommended prevention and care. First, do patients with eosinophilia-associated diseases have an altered course of COVID-19? Second, do patients with eosinopenia (now intentionally induced by biological drugs) have unique COVID-19 susceptibility and/or disease course? This is a particularly relevant question because eosinopenia is associated with acute respiratory deterioration during infection with the severe acute respiratory syndrome coronavirus 2, the causative agent of COVID-19. Third, do eosinophils contribute to the lung pathology induced during COVID-19 and will they contribute to immunopotentiation potentially associated with emerging COVID-19 vaccines? Herein, we address these timely questions and project considerations during the emerging COVID-19 pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.